Description

Bayer AG: An Insight Into Its Clinical Development, Regulatory Strategy

Bayer AG’s latest quarterly performance presents a mixed outlook, showing areas of growth and challenges. In terms of financial results, the company’s sales remained flat in the first half of 2025, with second-quarter net sales growing slightly by 1% in currency and portfolio-adjusted terms. Despite adverse currency movements, Bayer has successfully maintained a stable EBITDA, although foreign exchange headwinds impacted the top line with negative effects valued at around EUR 550 million. Core EPS for the period was EUR 3.72, and the company’s free cash flow was negative, at minus EUR 1.4 billion.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!